Quick Answer
Rani Therapeutics Holdings, Inc. reported Research And Development Expense of $20.21 million for the year ending 2025.
- Rani Therapeutics Holdings, Inc. showed a decrease of -24.3% in Research And Development Expense from 2024 to 2025.
- This data is from Rani Therapeutics Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $2.56 million | Q3 2020: $2.09 million | Q1 2021: $3.35 million | Q2 2021: $3.76 million | Q3 2021: $11.96 million | Q1 2022: $7.59 million | Q2 2022: $9.53 million | Q3 2022: $9.10 million | Q1 2023: $9.71 million | Q2 2023: $11.09 million | Q3 2023: $11.22 million | Q1 2024: $7.59 million | Q2 2024: $6.12 million | Q3 2024: $6.17 million | Q1 2025: $6.57 million | Q2 2025: $5.51 million | Q3 2025: $3.22 million.
- Over the full 6 years of available data (2020 to 2025), Rani Therapeutics Holdings, Inc.'s Research And Development Expense has grown by 67.8%.
- Historical annual values: Fiscal year 2025: $20.21 million | Fiscal year 2024: $26.68 million | Fiscal year 2023: $39.62 million | Fiscal year 2022: $36.61 million | Fiscal year 2021: $26.48 million | Fiscal year 2020: $12.04 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: